{"entity":{"id":"pethema","kind":"company","name":"PETHEMA (Programa Español de Tratamientos en Hematología)","aka":["PETHEMA","Fundación PETHEMA","PETHEMA Foundation","Programa Español de Tratamientos en Hematología"],"tldr":"Spain's academic haematology trials group, part of the Spanish Society of Haematology. Its working groups cover the leukaemias, myelodysplastic syndromes and, through GEM, myeloma.","summary":"PETHEMA, the Programa Español de Tratamientos en Hematología, describes itself as an independent academic cooperative group of haematologists and laboratory researchers from the hospitals of Spain's public health system, some private centres and hospitals in Europe and South America, belonging to the Sociedad Española de Hematología y Hemoterapia (SEHH). The Fundación PETHEMA is its instrument for clinical trials, observational and registry studies. Its working groups include GEM (myeloma), acute myeloid leukaemia, acute lymphoblastic leukaemia, chronic lymphocytic leukaemia, myelodysplastic syndromes and immune thrombocytopenia.\n\nAs PETHEMA Foundation it sponsors PEVOLAM (NCT04090736), a phase 3 trial of azacitidine with or without pevonedistat in older or unfit adults with newly diagnosed acute myeloid leukaemia.","asOf":"2026-11-03","links":[{"label":"Fundación PETHEMA: sobre PETHEMA","url":"https://www.fundacionpethema.es/sobre-pethema"},{"label":"PETHEMA: grupo de trabajo GEM","url":"https://www.fundacionpethema.es/grupo-de-trabajo/GEM"}],"tags":["cooperative-group"],"related":[],"cancers":["apl","aml","multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["la-fe-valencia","hospital-universitario-salamanca"],"pathways":[],"terms":[],"trials":["nct04090736"],"people":["miguel-sanz","maria-victoria-mateos"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["GEM myeloma group","PEVOLAM (NCT04090736)","Part of the Sociedad Española de Hematología y Hemoterapia"],"hq":"Madrid","country":"ES","companyType":"cooperative-group","website":"https://www.fundacionpethema.es","investors":[],"funding":[]},"route":"/companies/pethema/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"apl","kind":"cancer","name":"Acute promyelocytic leukaemia","route":"/cancers/apl/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"institution":[{"id":"la-fe-valencia","kind":"institution","name":"Hospital Universitari i Politècnic La Fe","route":"/institutions/la-fe-valencia/"},{"id":"hospital-universitario-salamanca","kind":"institution","name":"University Hospital of Salamanca / IBSAL","route":"/institutions/hospital-universitario-salamanca/"}],"trial":[{"id":"nct04090736","kind":"trial","name":"Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy","route":"/trials/nct04090736/"}],"person":[{"id":"maria-victoria-mateos","kind":"person","name":"María-Victoria Mateos","route":"/people/maria-victoria-mateos/"},{"id":"miguel-sanz","kind":"person","name":"Miguel A. Sanz","route":"/people/miguel-sanz/"}]}}